126 related articles for article (PubMed ID: 14518756)
1. Prophylactic brimonidine before LASIK.
Uretmen O; Ates H; Andaç K
J Refract Surg; 2003; 19(5):612. PubMed ID: 14518756
[No Abstract] [Full Text] [Related]
2. Effect of prophylactic brimonidine on bleeding complications and flap adherence after laser in situ keratomileusis.
Norden RA
J Refract Surg; 2002; 18(4):468-71. PubMed ID: 12160159
[TBL] [Abstract][Full Text] [Related]
3. Early flap dislocation with perioperative brimonidine use in laser in situ keratomileusis.
Nowroozzadeh MH
J Cataract Refract Surg; 2010 Feb; 36(2):368. PubMed ID: 20152647
[No Abstract] [Full Text] [Related]
4. Increased risk for flap dislocation with perioperative brimonidine use in femtosecond laser in situ keratomileusis.
Muñoz G; Albarrán-Diego C; Sakla HF; Javaloy J
J Cataract Refract Surg; 2009 Aug; 35(8):1338-42. PubMed ID: 19631117
[TBL] [Abstract][Full Text] [Related]
5. Incidence of brimonidine allergy in patients previously allergic to apraclonidine.
Williams GC; Orengo-Nania S; Gross RL
J Glaucoma; 2000 Jun; 9(3):235-8. PubMed ID: 10877374
[TBL] [Abstract][Full Text] [Related]
6. The adverse effect of perioperative brimonidine tartrate 0.2% on flap adherence and enhancement rates in laser in situ keratomileusis patients.
Walter KA; Gilbert DD
Ophthalmology; 2001 Aug; 108(8):1434-8. PubMed ID: 11470696
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
8. Apraclonidine and LASIK.
Aslanides IM; Tsiklis NS; Pallikaris IG; Jankov MR; Coskunseven E; Ozkilic E
Ophthalmology; 2005 Dec; 112(12):2238; author reply 2244. PubMed ID: 16325717
[No Abstract] [Full Text] [Related]
9. Update in glaucoma: the new pharmacotherapies. Brimonidine versus apraclonidine.
Crichton AC
Can J Ophthalmol; 1998 Aug; 33(5):254-5; discussion 257-8. PubMed ID: 9740952
[No Abstract] [Full Text] [Related]
10. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
11. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers.
Mungan NK; Wilson TW; Nischal KK; Koren G; Levin AV
J AAPOS; 2003 Feb; 7(1):69-70. PubMed ID: 12690374
[TBL] [Abstract][Full Text] [Related]
12. Use of brimonidine before LASIK with femtosecond laser-created flaps for the correction of myopia: a contralateral eye study.
Rodríguez-Galietero A; Martínez JV; Del Buey A; Bescós JA
J Refract Surg; 2010 Jan; 26(1):28-32. PubMed ID: 20199009
[TBL] [Abstract][Full Text] [Related]
13. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine tartrate ophthalmic solution 0.025% for redness relief: an overview of safety and efficacy.
Lee JS; Kim CY
Expert Rev Clin Pharmacol; 2022 Aug; 15(8):911-919. PubMed ID: 35951740
[TBL] [Abstract][Full Text] [Related]
15. Combination brimonidine and timolol.
Kerr NM; Gross KA; Tombleson M; Danesh-Meyer HV
Ophthalmology; 2010 Jan; 117(1):193-193.e1. PubMed ID: 20114113
[No Abstract] [Full Text] [Related]
16. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
17. Apparent central nervous system depression in infants after the use of topical brimonidine.
Carlsen JO; Zabriskie NA; Kwon YH; Barbe ME; Scott WE
Am J Ophthalmol; 1999 Aug; 128(2):255-6. PubMed ID: 10458196
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
20. [Development of conjunctival hyperemia with the use of a fixed combination of latanoprost/timolol: systematic review and meta-analysis of clinical trials].
Vinuesa-Silva JM; Vinuesa-Silva I; Pinazo-Durán MD; Soto-Alvarez J; Delgado-Ortega L; Díaz-Cerezo S
Arch Soc Esp Oftalmol; 2009 Apr; 84(4):199-207. PubMed ID: 19384760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
